Boston Scientific Corporation (BSX) Sinks 14.60% After Earnings, EPS Exceeds Estimates and Revenue Exceeds Estimates

2026-02-04 · Stocks · QuoteReporter

Post Earning Analysis

Boston Scientific Corporation (BSX) Sinks 14.60% After Earnings, EPS Exceeds Estimates and Revenue Exceeds Estimates

Boston Scientific Corp. is a leading medical device manufacturer founded in 1979, specializing in products for interventional medical procedures. Operating through MedSurg and Cardiovascular segments, it offers solutions in endoscopy, urology, neuromodulation, cardiology, and peripheral interventions. Headquartered in Marlborough, MA, the company continues to innovate in the medical field, enhancing patient outcomes worldwide.

Boston Scientific has recently faced significant challenges, as reflected in multiple news items highlighting the company’s performance and outlook. The company’s stock reached an 18-month low due to issues with its highly anticipated device, which has been described as a ‘sore spot’. Additionally, Boston Scientific’s stock hit a 52-week low following a soft outlook for 2026, indicating concerns about the company’s future revenue and earnings potential.

Despite these challenges, Boston Scientific reported Q4 earnings that beat expectations, suggesting some operational resilience. However, the company’s cautious revenue forecast for 2026 and the underperformance of a key division in sales forecasts have contributed to a sharp decline in its stock price.

These developments could have significant implications for investor confidence and the company’s market valuation. The mixed earnings results, coupled with a cautious outlook, suggest that Boston Scientific may be facing operational headwinds that could impact its financial performance in the near term. Investors and stakeholders in the medical technology sector will likely keep a close watch on how the company navigates these challenges moving forward.

The current price of the asset at $77.71 represents a significant decline of 14.6% today, indicating a sharp drop in investor confidence or response to a negative catalyst. This price is near its 52-week and year-to-date lows, both at $75.00, showing a minimal gain of 3.61% from these levels. This proximity to the lows suggests a bearish trend in the market for this asset.

The technical indicators reinforce this bearish outlook. The RSI at 21.14 is well into the oversold territory, which typically signals a potential for reversal; however, the consistent negative performance might dampen immediate recovery expectations. MACD at -2.04 further confirms the downward momentum, indicating that the current trend is strongly bearish.

The moving averages (MA20, MA50, MA200) are all significantly above the current price, with deviations ranging from -16.04% to -22.6%, highlighting a long-term negative trend. The asset is also performing poorly relative to its historical 52-week and year-to-date highs, having declined by approximately 29.03% from these peaks.

Overall, the asset is currently facing a strong downtrend with potential oversold conditions that could hint at a future reversal, though caution is warranted given the prevailing negative momentum.

Boston Scientific (BSX) announced its Q4 2025 financial results on February 4, 2026, revealing a significant increase in performance across various metrics. The company reported net sales of $5.286 billion for the quarter, marking a 15.9% increase on a reported basis and surpassing the forecasted range of 14.5% to 16.5%. Organically, sales grew by 12.7%. GAAP net income for common stockholders was $672 million, or $0.45 per share, up from $566 million, or $0.38 per share, in the prior year. Adjusted EPS also rose from $0.70 to $0.80.

For the full year, net sales totaled $20.074 billion, showing a 19.9% reported increase, and GAAP net income reached $2.898 billion, or $1.94 per share, compared to $1.853 billion, or $1.25 per share, in 2024. Adjusted EPS for the year was $3.06, up from $2.51.

The company’s segment performance was robust, particularly in the Cardiovascular and MedSurg segments, with significant growth noted in both U.S. and international markets. Boston Scientific also highlighted key product approvals and acquisitions, including the FDA approval of the FARAPOINT™ Pulsed Field Ablation Catheter and acquisitions of Penumbra, Inc., and Valencia Technologies Corporation.

Looking ahead to 2026, the company expects net sales growth to range from 10.5% to 11.5% on a reported basis and has projected an adjusted EPS of $3.43 to $3.49. For Q1 2026, anticipated net sales growth is between 10.5% to 12.0% on a reported basis, with an adjusted EPS forecast of $0.78 to $0.80.

Earnings Trend Table

The analysis of the EPS trends over the observed quarters reveals a consistent pattern of positive surprises, where the Reported EPS consistently exceeds the Estimate EPS. The data indicates a gradual increase in both estimated and reported EPS values over the time frame from October 2023 to February 2026. Initially, in October 2023, the estimated EPS was 0.48, with a reported EPS of 0.50, marking a surprise of 4.85%. This trend of outperformance continues, with the difference between estimated and reported EPS generally widening.

A significant increase in both estimated and reported EPS can be observed from the beginning of 2024, starting with an estimated EPS of 0.51 in January and a reported EPS of 0.55. By February 2026, the estimated EPS rises to 0.78 with the reported at 0.80. Notably, the largest positive surprise occurs in April 2025, with an 11.67% surprise, where the reported EPS of 0.75 greatly exceeds the estimate of 0.67.

This pattern suggests a robust financial performance, with the company consistently exceeding analyst expectations, which could be indicative of effective management and operational efficiency. The increasing trend in EPS estimates and reports also suggests growth expectations are being set and met progressively, which might be a positive indicator for investors looking at the company’s earnings consistency and potential for future growth.

The most recent rating changes for the securities in question reflect varying sentiments from different financial analysis firms regarding their market outlook and potential.

1. Erste Group – Downgrade by Outer (2025-10-03): The most recent action taken was a downgrade by Outer, moving from a “Buy” to a “Hold” rating. This change suggests a shift in perspective, possibly due to perceived risks or limited upside potential in Erste Group’s future performance. The absence of a target price indicates a cautious approach, focusing more on maintaining current holdings rather than expecting significant growth.

2. Oppenheimer – Upgrade (2025-09-08): Oppenheimer upgraded its rating from “Perform” to “Outperform” with a target price set at $125. This upgrade implies a positive adjustment in the firm’s expectations, forecasting that the stock will perform better than the broader market. The target price suggests a confident outlook on the stock’s growth potential.

3. Leerink Partners – Initiation (2025-06-16): Leerink Partners initiated coverage with an “Outperform” rating and a target price of $118. This initiation indicates a bullish stance from the outset, suggesting that Leerink Partners sees significant value and above-market performance in the near to mid-term.

4. Needham – Upgrade (2025-04-16): Needham upgraded its rating from “Hold” to “Buy” and set a target price of $113. This decision reflects a transition from a neutral to a more optimistic view on the stock’s future trajectory, indicating expected positive performance and potential for investment returns.

These changes collectively provide insights into the evolving market perceptions and firm-specific outlooks, highlighting a generally positive sentiment with varied degrees of confidence and expected performance metrics.

The current price of the stock stands at $77.71, which is notably lower than the average target price projected by various analysts. Oppenheimer has set a target price of $125 after upgrading the stock from “Perform” to “Outperform” on September 8, 2025. Similarly, Leerink Partners, upon initiating coverage on June 16, 2025, rated the stock as “Outperform” with a target price of $118. Earlier in the year, on April 16, Needham upgraded their rating from “Hold” to “Buy” and set a target price at $113. These target prices suggest a bullish outlook from analysts, indicating expectations for significant growth in the stock’s value.

In contrast, Erste Group downgraded the stock from “Buy” to “Hold” on October 3, 2025, without specifying a target price, which might indicate some reservations about the stock’s short-term growth prospects or a perceived alignment with its current market price.

Overall, the consensus among analysts leans towards a positive growth trajectory for the stock, with a substantial gap between the current market price and their target prices, suggesting potential underpricing or expected future growth.

Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.